NEW YORK (GenomeWeb) – Israeli biotech firm MeMed said that it has won a €2.3 million ($2.6 million) grant from the European Commission to support clinical testing of its ImmunoXpert test, a protein diagnostic for distinguishing between bacterial and viral infections.

According to the company, the funds will be used to put the test in pediatric departments in Italy and Germany. It aims to monitor 1,200 children with either respiratory tract infections or fevers without source, assessing both the clinical utility and cost-effectiveness of the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.